Evaxion Biotech Files 6-K, Incorporates by Reference

Ticker: EVAX · Form: 6-K · Filed: 2025-04-07T00:00:00.000Z

Sentiment: neutral

Topics: filing, sec, registration

Related Tickers: EVX

TL;DR

EVX files 6-K, rolls info into existing S-8/F-3/F-1 filings.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on April 7, 2025, for the month of April. This report is for a foreign private issuer and is incorporated by reference into several of Evaxion's existing registration statements on Forms S-8 and F-3, as well as multiple Form F-1 filings. The company is incorporated in G7 and its fiscal year ends on December 31.

Why It Matters

This filing indicates ongoing reporting requirements and the integration of information into existing securities offerings, which is standard for companies with multiple public filings.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain new material information or significant corporate events.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing by Evaxion Biotech A/S?

This Form 6-K is a report of a foreign private issuer for the month of April, serving to incorporate information by reference into existing registration statements.

Which registration statements does this 6-K filing get incorporated into?

It is incorporated into Evaxion Biotech A/S's registration statements on Form S-8 (File No. 333-255064), Form F-3 (File No. 333-265132), and multiple Form F-1 filings (File Nos. 333-266050, 333-276505, 333-279153, 333-283304), and Form F-3 (File No. 333-285778).

What is Evaxion Biotech A/S's Commission File Number?

Evaxion Biotech A/S's Commission File Number is 001-39950.

When is Evaxion Biotech A/S's fiscal year end?

Evaxion Biotech A/S's fiscal year ends on December 31.

Where is Evaxion Biotech A/S's principal executive office located?

Evaxion Biotech A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

From the Filing

0001171843-25-002044.txt : 20250407 0001171843-25-002044.hdr.sgml : 20250407 20250407060016 ACCESSION NUMBER: 0001171843-25-002044 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20250404 FILED AS OF DATE: 20250407 DATE AS OF CHANGE: 20250407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25816235 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 4552656554 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_040425.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ 	Form 40-F ☐ INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Furnished as Exhibit 99.1 to this Report on Form 6-K is the convening notice for the Annual General Meeting (the “Meeting”) of Evaxion Biotech A/S (the “Company”), to be held on April 30, 2025 at 14:00 (CEST). Furnished as Exhibit 99.2 to this Report on Form 6-K is the form of Proxy for the Company’s Annual General Meeting. Exhibits Exhibit No. Description 99.1 Notice of Annual General Meeting 99.2 Proxy for Annual General Meeting SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Evaxion Biotech A/S Date: April 4, 2025 By: /s/ Christian Kanstrup Christian Kanstrup Chief Executive Officer EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 4 April 2025 NOTICE OF ANNUAL GENERAL MEETING EVAXION BIOTECH A/S 30 APRIL 2025 AT 14:00 (CEST) The board of directors hereby convenes the annual general meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76 28 63 (the "Company"), to be held on 30 APRIL 2025 AT 14:00 (CEST) at Evaxion Biotech A/S, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. AGENDA 1. Election of the chairman of the meeting 2. The board of directors' report on the Company’s activities in the past year 3. Presentation of the audited annual report for adoption 4. Resolution on the allocation of profit or coverage of loss, cf. the adopted annual report 5. Election of members to the board of directors 6. Election of auditor 7. Any motion from the board of directors and/or the shareholders 8. Proposal to authorize the chairman of the meeting 9. Miscellaneous 2 COMPLETE PROPOSALS 1. Election of the chairman of the meeting The board of directors proposes that attorney-at-law Lars Lüthjohan be elected as chairman of the gener

View on Read The Filing